Bremelanotide Nasal Spray vs Injection: Which Route, and Why?
The FDA-approved form of bremelanotide is the subcutaneous injection, and that is not an accident: the nasal route was explored earlier in development and set aside over inconsistent absorption and dose-related effects. Compounded nasal sprays now revisit that route for needle-averse patients. What each route offers, what each gives up, and how to think about the choice.
Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 8 min read
Key facts
The FDA-approved bremelanotide product, Vyleesi®, is a single-use subcutaneous autoinjector. No nasal bremelanotide product is FDA-approved.
Bremelanotide's early development included intranasal delivery, which was set aside amid inconsistent absorption and dose-related concerns; the approved program proceeded subcutaneously.
Injection delivers a known dose with predictable absorption; nasal delivery varies with mucosal condition, technique, and formulation.
Compounded nasal sprays are patient-specific pharmacy preparations, typically chosen for needle aversion, with dosing set by the prescriber.
All routes carry the same molecule's rules: usage ceilings, blood-pressure cautions, nausea as the signature side effect.
Why is the approved product an injection at all?
Peptides are fragile cargo. Swallowed, they are digested; delivered through mucosa, their absorption depends on tissue conditions; injected subcutaneously, they enter circulation with the predictability regulators and prescribers prize. Bremelanotide's own development history recorded this arc: intranasal delivery was explored in earlier programs and set aside, with inconsistent absorption and dose-related effects among the cited reasons, and the pivotal trials that produced approval ran subcutaneously.
That history is the plain starting point for the route conversation: the injection is not merely a corporate preference, it is the route whose dose-to-effect relationship the entire evidence base was built on.
What does the nasal route offer, and what does it trade away?
The offer is obvious and real: no needle. For a meaningful share of patients, that single fact decides whether an as-needed peptide is usable at all, and mucosal delivery also skips first-pass metabolism, with onset in a broadly similar conversation to injection when absorption cooperates. The trade is variability: congestion, technique, spray angle, and formulation all move how much drug actually arrives, so the effective dose is less certain spray to spray than shot to shot.
Compounded sprays manage this with prescriber-set concentrations and titration guidance, and users are typically counseled to keep conditions consistent: same technique, clear nasal passages, and no casual dose-stacking when an underwhelming spray was probably an absorption miss. That last habit matters, because the molecule's blood-pressure and nausea profile does not distinguish between intended and accidental double doses.
3/mo CHROMA23+ Membership, medication priced separately, every cost shown first.
How do the compounded formats differ from the approved autoinjector?
The approved product is a fixed-dose, single-use autoinjector: mechanically simple, dose-certain, no drawing or measuring. Compounded alternatives span injections drawn from multi-dose vials at pharmacy-set concentrations, nasal sprays, and occasionally other mucosal formats, each a patient-specific preparation under the compounding framework, none FDA-approved, all inheriting their evidence indirectly from the approved program. The practical mechanics of vial-and-syringe use, storage, drawing, sharps, mirror the general guidance in our injection logistics guide.
Storage differs by format and formulation: peptide sprays and vials generally live refrigerated, with beyond-use dates set by the pharmacy, and heat excursions are discard-and-call events rather than judgment calls. The label on your specific product governs over anything generic.
How does a physician actually choose the route with a patient?
The decision tree in practice is short. If the approved autoinjector is accessible and acceptable, its dose certainty and evidence pedigree make it the default conversation. Needle aversion strong enough to prevent use is a genuine clinical fact, not a preference to be argued out of, and it is the primary door to the nasal conversation. From there the prescriber weighs blood-pressure history, the rest of the medication list, cost and availability realities, and whether the patient's expectations survive the variability caveat.
Whichever route emerges, the molecule's rulebook rides along unchanged: the usage ceilings, the cardiovascular cautions, the nausea planning, and the diagnosis question underneath it all, covered in our complete PT-141 guide.
Frequently asked questions
Is the nasal spray gentler on nausea than the injection?
There is no controlled comparison to cite, and the anecdote pool points both directions, likely because absorbed dose drives nausea and nasal absorption varies. What is documented is that nausea tracks the molecule, not the needle.
Can I switch between the injection and the spray?
Under prescriber direction, yes, and the direction matters: doses do not translate one-to-one across routes with different absorption. Switching is a re-dosing conversation, the same principle covered in our GLP-1 switching guide, applied to a peptide.
How long does a compounded spray bottle last?
Two clocks run: doses per bottle at your prescribed spray count, and the beyond-use date from the pharmacy, whichever ends first. Peptide stability is the binding constraint, so a half-full bottle past its date is done, not a bonus.
Are the peptide sprays sold by research-chemical sites the same thing?
No, and this category is among the most counterfeited corners of the peptide gray market. No prescription, no licensed pharmacy, no label, no recourse: outside the regulated system entirely, for a molecule with real cardiovascular cautions. The legitimacy checklist in our compounding legality explainer applies with full force.
About CHROMA23®
CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.